Psychiatric and neurological disorders are among the most complex, poorly understood and debilitating diseases in medicine. Abrogating gene function using knockout animals is one of the primary means of examining the pathophysiological significance of a given gene product and has been used successfully in models of neuropsychiatric disorders. However, the developmental compensations that may potentially arise from such approaches are problematic and difficult to assess. The recent discovery of RNAi (RNA interference), as a highly efficient method for gene knockdown, has opened up the possibility for its application in examining the potential role of genes in adult brain function and/or disorders. Recent efforts have focused on applying RNAi-based knockdown to understand the genes implicated in neuropsychiatric disorders. We have developed a method of gene knockdown involving chronic infusion of siRNA (short interfering RNA) using osmotic minipumps. We have silenced a number of genes including those for the serotonin and dopamine transporter. Such tailoring of tools that deliver RNAi in the brain will significantly aid in our understanding of the complex pathophysiology of neuropsychiatric disorders where there is an immensely unmet medical need.
Introduction
Disorders of the central nervous system are among the most complex, poorly understood, and debilitating diseases. The burgeoning advances in functional genomic technologies have led to the identification of a vast number of novel genes that are potentially implicated in the pathophysiology of such disorders. However, many of these candidate genes have not yet been functionalized and require validation in vivo. Traditionally, abrogating gene function is one of the primary means of examining the physiological significance of a given gene product. Indeed over the past decade we have used such
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knockout techniques to try and understand the role of a variety of neurotransmitter systems in brain function. These include the noradrenergic [1, 2] , glutamatergic [3, 4] and GABAergic [5] [6] [7] systems (GABA is γ -aminobutyric acid). However, caution is needed when interpreting data from knockout animals as behavioural analysis can uncover unexpected compensations, effects on other gene products, altered endocrine and neuronal feedback loops, and a lack of control over the temporal and spatial impact of the genetic manipulation [8] . Further, it is becoming clear that epigenetic and environmental factors need to be considered as these may give rise to ectopic expression of other proteins that may markedly influence behaviour. Thus it is also possible that the direction of a behavioural change in a conventional mutant animal may not be in agreement with acute pharmacological manipulation of the very same protein. Furthermore, pleiotropy, whereby a single gene can influence multiple phenotypic traits, is a common occurrence adding further complexity.
In response to such problems, several methods have been developed for gene ablation or knockdown in adult animals [9] . The recent discovery of RNAi (RNA interference), as a highly efficient method for gene knockdown, has been one of the major breakthroughs in molecular medicine. In vivo application of RNAi is further demonstrating the promise of this technology. In the present paper, we discuss recent efforts focused on applying RNAi-based knockdown to understand the genes implicated in neuropsychiatric disorders.
RNAi
RNAi has emerged as one of the most important concepts in modern biological research. Although it is only a recent discovery, first demonstrated in the worm, Caenorhabditis elegans, in 1998 [10] , and three years later in mammalian cells [11] , it has already garnered the 2006 Nobel Prize in Physiology or Medicine. RNAi is a cellular surveillance phenomenon that serves to repress viral infections, transposable elements and repetitive genes, but also to regulate gene expression as well as normal cell development [12] . RNAi is a post-transcriptional gene-silencing event that is triggered with the cytoplasmic presence of long dsRNAs (doublestranded RNAs). dsRNAs are cleaved by the enzyme, Dicer, to generate siRNAs (short interfering RNAs), which are ∼21-25 nt-long dsRNAs containing 5 phosphorylated ends and 3 2-nt overhangs on each strand [13] . siRNAs get incorporated into a multiprotein RISC (RNA-induced silencing complex) that unwinds the siRNA duplex. The siRNA strand retained in RISC then guides the entire complex to a target mRNA. Depending on the complimentarity of the target mRNA sequence with that of the siRNA guiding strand, RISC initiates the endonucleolytic cleavage or translational arrest of the target mRNA [12, 14] .
RNAi offers a rapid means of somatic gene manipulation that not only is more potent than the conventional antisense oligodeoxynucleotide or ribozyme approaches, but also mimics the idealistic pharmacological means of target validation by only partially inhibiting the target gene function. As a result, RNAi has been increasingly used, to generate a dsRNAmediated loss-of-function phenotype for deciphering the function(s) of novel genes [15] . However, the in vivo delivery of siRNA faces a variety of hurdles in the extracellular environment in addition to various barriers for the intracellular uptake [16] . Addressing those issues is crucial for efficient in vivo delivery of siRNA in preclinical animal models for drug target validation. Nonetheless, an effective knockdown of exogenous as well as endogenous genes has, since, been demonstrated in several mammalian organs (liver, lung, spleen, kidney, pancreas and even skeletal muscle) using minimally intricate procedures for administering siRNA, such as the hydrodynamic intravascular injections, nasal instillations or, simply, local injections. Subsequently, RNAi has found an immense success in its application to explore the pathophysiology and potential therapeutics in animal models of viral infections, auto-immune and inflammatory diseases [16, 17] . However, the use of RNAi in understanding the pathophysiology of neuropsychiatric disorders faces the daunting task of targeting gene expression in the mammalian brain [12] .
RNAi in the brain
Despite the well-illustrated ability of siRNA to reduce gene expression in cultured mammalian neurons and glial cells, the brain poses a 2-fold hurdle for the successful application of RNAi. At the forefront, the blood-brain barrier restricts the passive entry of materials from the peripheral circulation, thus rendering the systemic approach almost ineffective for eliciting siRNA-mediated gene knockdown in the brain. Secondly, a high degree of cellular diversity as well as networking adds to the complexity in achieving the desired gene knockdown within a specific set of cells in the brain. One of the first and most obvious approaches has been the use of local injections into specific brain regions. This includes studies where siRNA is injected directly into the hypothalamus (targeting the gene for agouti-related protein [18] or the pre-proorexin gene [19] ), into the brainstem [targeting the α 2A adrenoreceptor) [20] , into the ventral tegmental/substantia nigra [targeting tyrosine hydroxylase and DAT (dopamine transporter)] [21] or into the cortex [targeting the transcription factor STAT (signal transducer and activator of transcription)] [22] . Such local injections of naked siRNA restrict its entry to just a small number of cells that are in close proximity to the injection site. Electroporation serves to increase the extent of siRNA delivery. Akaneya et al. [23] have successfully used the application of an electrical pulse to enable greater delivery across the plasma membrane for genes targeting AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) glutamate receptor 2 or cyclo-oxygenase 1, in the hippocampal CA1 region and visual cortex of neonatal rats [23] .
Delivery aided by osmotic minipumps
The above-discussed methods, in addition to viral-mediated delivery of shRNA (small hairpin RNA) (see [24] ), are efficient methods for the phenotyping of genes expressed in a few, distinct loci in the brain. However, they are less amenable for investigating the functional role of genes that are broadly expressed, and contribute to a (patho)physiological state by influencing a complex neuronal circuitry involving more than one brain region. Therefore, to facilitate the functional assessment of such ubiquitously expressed genes and also to enable a rapid and regionally unbiased phenotyping of novel genes in the brain, our efforts have focused on whether siRNA could be efficiently delivered to produce efficient, widespread gene-silencing throughout the whole neuroaxis.
One of the major breakthroughs has been the demonstration of prolonged siRNA administration, using osmotic minipumps, that circumvents the use of transfection or electroporation techniques associated with possible neurotoxic effects, and produces widespread gene knockdown throughout the brain [25, 26] . An osmotic minipump contains a high-osmolality chamber that surrounds a flexible, yet impermeable reservoir filled with the siRNA-containing vehicle. Subsequent to the subcutaneous implantation of this minipump, extracellular fluid enters through an outer semi-permeable membrane into the high-osmolality chamber, thereby compressing the reservoir to release siRNA at a controlled, predetermined rate. siRNA, released from the pump, is directed via a catheter to a stereotaxically placed cannula for infusion into the brain or spinal cord. One of the first examples of such an approach was siRNA intrathecally infused in rats, for up to 6 days, in order to potentially knockdown the pain-related cation channel, P2X 3 [27] . Indeed, a significant (40%) decrease in P2X 3 expression was obtained in the dorsal root ganglia, along with down-regulated protein levels in the dorsal horn of the spinal cord. As expected, siRNAmediated knockdown of the channel markedly diminished the responsiveness of rats to pain evoked by a P2X 3 agonist, α,β-methylene ATP, as well as in a neuropathic pain model. More importantly, no signs of neurotoxicity, with respect to neuro-anatomical damage, spinal inflammation or hindlimb paralysis, were noted with siRNA infusions at the rates as high as 0.4 mg/day for up to 6 days. Intrathecal siRNA infusion takes advantage of a direct access to neurons within specific layers of the spinal cord. Furthermore, a rapid clearance from the intrathecal space reduces the likelihood of any non-specific effects. On these lines, we recently assessed whether intracerebroventricular infusion of siRNA, using osmotic minipumps, would lead to a specific knockdown of gene expression in the brain [25, 26] .
A transgene, EGFP (enhanced green fluorescent protein), was targeted in mice that expressed EGFP almost uniformly throughout the brain, thus enabling us to determine the extent of siRNA-induced gene knockdown in the brain [26] . Infusions into the dorsal third ventricle were performed, for 7 or 14 days, with an aim of achieving a bilateral and widespread distribution of siRNA in the brain. In fact, a bilateral, time-dependent and specific knockdown of EGFP mRNA, as well as protein, was attained in a number of brain structures. This knockdown was widespread along the rostro-caudal (∼5.7 mm, prefrontal cortex to the substantia nigra), dorsoventral (e.g. hippocampus and hypothalamus) and mediolateral (e.g. thalamus and amygdala) axes of the brain. However, a few regions proximal to the dorsal third ventricle, such as the globus pallidus and habenula, were remarkably resistant to the temporality of siRNA response. The magnitude of gene knockdown also varied among brain regions, with the hippocampal neurons demonstrating maximal (∼50%) gene knockdown in the brain. Such an effect would suggest that, although siRNA infusion appears to have a general spread of action in the brain, its gene-silencing efficacy may be dictated by the cell type(s) constituting each target region. Further, bearing in mind the overexpression and stability of EGFP in transgenic mice, the present study probably underestimated the extent as well as efficacy of siRNA-induced gene knockdown in the brain. This became apparent upon targeting an endogenous gene that codes for the DAT, in the substantia nigra compacta and ventral tegmental area, far caudal to the siRNA infusion site. DAT controls the temporal and spatial activity of dopamine released into the synapse, by facilitating a rapid uptake of the neurotransmitter into presynaptic terminals. DAT is therefore a key regulator of dopamine actions on locomotion, emotion, reward and cognition, and implicated in the aetiology and pharmacotherapy of hyperkinetic disorders, such as attention-deficit hyperactivity disorder, drug dependence, neurodegenerative disorders, such as Parkinson's disease, and disorders of mood, such as depression. DAT mRNA levels were significantly reduced (by 33%) upon infusion of an unmodified siRNA into the dorsal third ventricle, using a two-week osmotic minipump [26] . Down-regulation was evident also with the DAT protein that is translocated down the axons of midbrain dopaminergic neurons to projection areas into the striatum, nucleus accumbens and olfactory tubercles. Autoradiographic analysis of DAT-binding sites showed a reduction in the order of ∼50% in these brain areas. Concomitant to the siRNA-induced knockdown of DAT, a time-dependent hyperlocomotor phenotype was established in mice, similar to that obtained upon infusing a potent and pharmacologically selective DAT inhibitor. Furthermore, the 6-9 days time lag required to detect a hyperlocomotor phenotype in the siRNA-infused mice was consistent with the ∼7 day-turnover rate of DAT protein in vivo. The hyperlocomotor phenotype attained in mice receiving DAT siRNA also is qualitatively similar to that exhibited by the DATknockout mice [28] , representing animal models of hyperkinetic disorders, such as the attention-deficit hyperactivity disorder. Therefore these results provide a lucid illustration of gene knockdown in the brain, adequately achieved with intracerebroventricular infusions of siRNA, that produces not only a behavioural phenotype for target validation, but also animal models of neuropsychiatric disorders.
More recently, we provided an additional proof-of-concept by targeting the SERT (serotonin transporter) gene implicated in the aetiology of several psychiatric illnesses, including anxiety and depression. In the present study, twoweek siRNA infusions into the dorsal third ventricle specifically reduced the mRNA levels of SERT, by ∼30%, in the dorsal and median raphe nuclei. This decrease in mRNA levels also translated into a specific reduction in the levels of SERT protein widespread in the brain. Consequently, an antidepressant-like behaviour was noted in the mouse forcedswim test, identical with the response obtained from mice receiving a pharmacologically selective inhibitor of SERT. Interestingly, SERT-deficient mice were used to ascertain the role of SERT in the aetiology of depression versus the antidepressant action of SSRIs (selective serotonin-reuptake inhibitors) [29] . However, these mice under certain circumstances display paradoxical depression-related behaviour, which has been attributed to the developmental changes that result from early-life absence of SERT [30, 31] . Indeed, an elevated propensity towards abnormal emotional behaviour is noted in adult animals chronically treated with antidepressants during early development [30, 32] , or in individuals genetically expressing low levels of SERT [33] .
The ability to down-regulate SERT efficiently in the adult brain using RNAi is of great importance in addressing the functional consequence of SERT deficiency at different stages of development. Therefore, although SERT-knockout mice may represent a useful model for investigating disorders that involve genetic alterations in SERT during early life [31, 34] , RNAi-induced knockdown provides a better model for examining the role of SERT in the adult brain.
Altogether, these studies demonstrate the efficiency of intracerebroventricular-infused siRNA to knockdown gene expression in a broad expanse of the brain, encompassing areas far distal to the infusion site. This approach precludes the need of directly injecting siRNA into the area of gene expression, thus avoiding a possible neuro-anatomical damage in the injection site with consequent undesirable behavioural effects. Nevertheless, an interesting question that emerges is, how does the siRNA reach its distal targets? Is it solely via its presence in the intracerebroventricular flow or alternatively due to an unknown mechanism of retrograde and/or anterograde transport along neurons? Further investigations on this aspect may uncover the potential utility of siRNA as a tracer to precisely mark the neuronal networking among different brain regions. In any case, siRNA infusion into the dorsal third ventricle, using osmotic minipumps, serves as an effective means of producing a specific and bilateral knockdown of gene expression in the brain for validation of targets implicated in neurological and psychiatric disorders. Besides evading the need for repeated siRNA injections, the use of osmotic minipumps enables a continual time-dependent evaluation of the phenotype resulting from gradually increasing knockdown of the gene. The delivery of siRNA can also be potentially extended to any desirable length of time by replacing the emptying minipump with newly filled pumps, thus making it suitable for phenotyping of genes with protracted mRNA and/or protein half-lives. In addition, replacement of the minipump allows for reversibility and subsequent verification of the gene-knockdown phenotype. However, an obvious caveat to the use of the minipump-infused siRNA approach is the expenditure associated with the synthesis of siRNA, contingent on the concentration and infusion period required in order to achieve a stable gene knockdown.
Conclusions
Over the past five years, RNAi has rapidly emerged as a key tool for analyses of gene function. RNAi has, by now, revolutionized the world of functional genomics; its translation from in vitro to in vivo holds the key to its successful application in the target validation process and further down the road in therapeutic applications, and first clinical trials are already ongoing. Delivery of RNAi to the brain is a crucial factor in its in vivo use for validation of targets implicated in neuropsychiatric disorders. Our results demonstrate that sequence-specific gene knockdown is achievable and that this knockdown in the brain produces a behavioural phenotype similar to that demonstrated by knockout or pharmacological inhibitors. Of key importance, the extent of knockdown is widespread (∼6.7 mm rostro-caudal spread) and adequate for validation of genes with a ubiquitous expression profile in the brain. Another benefit is that the background genetic strain of animal can be optimized for the specific readout required. This is of particular importance in behavioural experiments where a large strain variation occurs [35] . Overall this approach should aid in acute and reversible phenotyping of rodents and should be applicable for target validation of novel therapies for psychiatric and neurological disorders.
